Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

  1. de Wit, R.
  2. Powles, T.
  3. Castellano, D.
  4. Necchi, A.
  5. Lee, J.-L.
  6. van der Heijden, M.S.
  7. Matsubara, N.
  8. Bamias, A.
  9. Fléchon, A.
  10. Sternberg, C.N.
  11. Drakaki, A.
  12. Yu, E.Y.
  13. Zimmermann, A.H.
  14. Long, A.
  15. Walgren, R.A.
  16. Gao, L.
  17. Bell-McGuinn, K.M.
  18. Petrylak, D.P.
Revue:
British Journal of Clinical Pharmacology

ISSN: 1365-2125,  0306-5251

Année de publication: 2022

Volumen: 88

Número: 7

Pages: 3182-3192

Type: Article

DOI: 10.1111/BCP.15233 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus